Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Clinical characteristics and prognostic factors in myeloid blast-Phase chronic myeloid leukemia

Huifang Zhao, Yingling Zu, Yanli Zhang Nov 03, 2025 pp. 7287-7287 10.1182/blood-2025-7287

Abstract Background The advent of the tyrosine kinase inhibitor (TKI) era has resulted in long-term survival for patients with chronic-phase...

Evaluating the efficacy of brief neurocognitive assessments in adults and adolescents with sickle cell disease

Elizabeth Doss, Lisbel Gonzalez, Lydia Musula et al. Nov 03, 2025 pp. 7963-7963 10.1182/blood-2025-7963

Abstract Introduction: Sickle cell disease (SCD) is a common, life-threatening inherited hemoglobin disorder characterized by both acute and...

Multi‑omics analysis of Del20q reveals PHF20 haploinsufficiency and an HDAC2-centered epigenetic circuit in myeloid neoplasms

Mark Orland, Arda Durmaz, Zachary Brady et al. Nov 03, 2025 pp. 5616-5616 10.1182/blood-2025-5616

Abstract Deletion of chr. 20q (del20q) is detected in 5-8% of myeloid neoplasms and is one of the most frequent age-related CHIP events, ari...

Non-viral ultrasound-mediated delivery of an episomal FVIII expression vector enables durable FVIII protein production at therapeutic levels in non-human primates

Ivan Krivega, Margarita Krivega, Elizabeth Del Greko et al. Nov 03, 2025 pp. 1066-1066 10.1182/blood-2025-1066

Abstract Hemophilia A (HemA) is a monogenic bleeding disorder caused by mutations in the F8 gene, which encodes coagulation Factor VIII (FVI...

Changes in long-term bone health in patients receiving avapritinib for the treatment of indolent systemic mastocytosis in the pioneer study

Mariana Castells, Vishnu Sundaresh, Jason Gotlib et al. Nov 03, 2025 pp. 5582-5582 10.1182/blood-2025-5582

Abstract Introduction: Indolent systemic mastocytosis (ISM) is a clonal mast cell disease driven by the KIT D816V mutation in ~95% of patien...

Global sex- and income-stratified disparities in mortality due to tobacco-associatedleukemia, 1990–2021

Shree Rath, Amar Lal, Hyma Polimera et al. Nov 03, 2025 pp. 8186-8186 10.1182/blood-2025-8186

Abstract Abstract Introduction: Leukemia, a heterogeneous group of hematologic malignancies, has established association...

SLM124: A first-in-class anti-CD84 antibody-drug conjugate demonstrates potent anti-tumor activity and favorable tolerability in hematologic malignancy models

Chan Whiting, Leia Smith, May Sutherland et al. Nov 03, 2025 pp. 5089-5089 10.1182/blood-2025-5089

Abstract Background: The Signaling Lymphocytic Activation Molecule Family (SLAMF5), or CD84, is a novel target broadly expressed across a sp...

Clinics and clicks: Understanding hematology healthcare delivery utilization and preferences in the digital era

Rosalyn Marar, Nadia Toumeh, Savannah Liddell et al. Nov 03, 2025 pp. 2864-2864 10.1182/blood-2025-2864

Abstract Background: The landscape of healthcare delivery in hematology has undergone significant transformations with the increasing adopti...

Selinexor-based regimens in triple-class exposed or refractory multiple myeloma: A real-world analysis of efficacy and safety in 18 patients

Wenjing Li, Yin Wu, Chuanying Geng et al. Nov 03, 2025 pp. 7590-7590 10.1182/blood-2025-7590

Abstract Background: Patients with triple-class exposed (TCE) or triple-class refractory (TCR) multiple myeloma (MM) have limited therapeuti...

Targeting bcaa metabolism induces synthetic lethality in DNMT3A-mutated acute myeloid leukemia

Chengyang Xu, Yongjia Wei, Jia Yu et al. Nov 03, 2025 pp. 3223-3223 10.1182/blood-2025-3223

Abstract DNA methyltransferase 3A (DNMT3A)-mutant acute myeloid leukemia (AML) exhibits epigenetic dysregulation and chemoresistance, but th...

Impact of MYC alterations in de novo large B-cell lymphoma: An italian single center experience

Chiara Pagani, Alessandro Re, Angela Passi et al. Nov 03, 2025 pp. 5443-5443 10.1182/blood-2025-5443

Abstract Introduction: Large B-cell lymphoma (LBCL) with translocations involving MYC (MYC-T) and BCL2 (BCL2-T) +/- BCL6 (BCL6-T) (DHL-THL)...

Artificial intelligence–supported insight generation to inform medical education priorities in multiple myeloma

Carley Yawn, Sarah Nisly Nov 03, 2025 pp. 2868-2868 10.1182/blood-2025-2868

Abstract Introduction: The rapidly evolving treatment landscape in multiple myeloma (MM) presents a challenge for contin...

TET2 mutations drive cell-autonomous type I interferon production and selective advantage through TRIM4 silencing

Baosen Jia, Igor Fijalkowski, Manon Jaud et al. Nov 03, 2025 pp. 976-976 10.1182/blood-2025-976

Abstract TET2 mutations cause clonal expansion of hematopoietic stem and progenitor cells (HSPCs) and chimeric antigen receptor (CAR)-expres...

Clinical features of castleman disease: Single institution experience

Joseph Elengickal, Mattie Thomas Nov 03, 2025 pp. 6571-6571 10.1182/blood-2025-6571

Abstract Background: Castleman disease (CD) is an extremely rare lymphoproliferative disease presenting with abnormal lymph node enlargement...

Hematopoietic stem cell transplantation in 746 children with osteopetrosis: A study of the inborn errors working party of the EBMT

Robert Chiesa, Michael H. Albert, Patrick Gilbert et al. Nov 03, 2025 pp. 165-165 10.1182/blood-2025-165

Abstract Introduction Osteopetrosis (OP) is a group of rare inherited conditions characterized by dysfunctional osteoclasts, leading to hypo...

HIF-1 and HIF-2 pathways in regulation of hepcidin

Ivan Sergeev, Josef Prchal, Seyed Mehdi Nouraie et al. Nov 03, 2025 pp. 1131-1131 10.1182/blood-2025-1131

Abstract Hepcidin, the master regulator of iron metabolism, inhibits absorption and release of iron from macrophages through interaction wit...

Integrating bispecific antibodies into VA oncology care: A multidisciplinary protocol and education model from visn 20

Nicholas Burwick, Melissa Glasner, Jasleen Chalal Nov 03, 2025 pp. 6198-6198 10.1182/blood-2025-6198

Abstract Multiple myeloma (MM) is a disabling hematologic malignancy requiring continuous therapeutic innovation and timely intervention to...

Non-invasive Mantle Cell Lymphoma risk stratification by inference of tumor proliferation from cfDNA

Amirsaman Ashtari, Jurik Mutter, Benoit Tessoulin et al. Nov 03, 2025 pp. 1789-1789 10.1182/blood-2025-1789

Abstract Background: Variability in tumor proliferation is a key prognostic factor in Mantle Cell Lymphoma (MCL). However, its measurement b...

Real-world treatment patterns and clinical outcomes among patients with paroxysmal nocturnal hemoglobinuria treated with iptacopan in the United States

David Dingli, Soyon Lee, Nicholas Kuypers et al. Nov 03, 2025 pp. 1429-1429 10.1182/blood-2025-1429

Abstract Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening hematological disorder affecting ≈24 per 1,000,...

Therapeutic targeting of the recurrent mutant TP53R248Q neoantigen by T cell receptor-engineered T cells in human cancers

lianghua shen, Jian Xu, Ziyu Chen et al. Nov 03, 2025 pp. 4135-4135 10.1182/blood-2025-4135

Abstract Background Malignant tumors with TP53 mutations exhibit poor therapeutic outcomes and high recurrence rates. T cell receptor (TCR)-...

Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial

Noemi Puig, Matthew Nichols, Cristina Agullo et al. Nov 03, 2025 pp. 2238-2238 10.1182/blood-2025-2238

Abstract Background: Mass spectrometry (MS) is increasingly used to detect monoclonal proteins (MPs) in patients with monoclonal gammopathie...

Optimizing Bcl11b timing enhances natural killer cell differentiation and cytotoxicity from human pluripotent stem cells for effective immunotherapy

Akhilesh Kumar, Bin Zhang, Andrew Baldys et al. Nov 03, 2025 pp. 3153-3153 10.1182/blood-2025-3153

Abstract Human hematopoietic stem cells (HSCs) derived from induced pluripotent stem cells (iPSCs) are revolutionizing regenerative medicine...

Socioeconomic, racial, and hospital-level disparities in inpatient mortality among patients with plasma cell dyscrasias: A 2016-2022 nationwide analysis from the national inpatient sample

Hector Garcia Pleitez, Nehemias Guevara, Andrea Ortiz Maldonado et al. Nov 03, 2025 pp. 8129-8129 10.1182/blood-2025-8129

Abstract Introduction: The discovery of new therapeutic options in plasma cell dyscrasias (PCDs) has advanced significantly over the last de...

Safety and outcomes of venetoclax initiation in patients with  AML and hyperleukocytosis

Sanjana Nethagani, Nolan Holley, Hiba Khan et al. Nov 03, 2025 pp. 3410-3410 10.1182/blood-2025-3410

Abstract Introduction: Venetoclax in combination with hypomethylating agents has improved outcomes in acute myeloid leuk...

Evaluation of treatment responses to methotrexate and cyclophosphamide among T-LGL patients with and without Y640F and D661Y STAT3 mutations – a retrospective observational study

Emma Gray, Nathan Roberts, Danh Tran et al. Nov 03, 2025 pp. 1876-1876 10.1182/blood-2025-1876

Abstract Introduction T-cell large granular lymphocytic leukemia (T-LGL) is a rare chronic lymphoproliferative disorder characterized by a c...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page